London
20 °C
Manchester
19 °C
Glasgow
14 °C
Dublin
15 °C
Belfast
Washington
Denver
Atlanta
Dallas
33 °C
Houston Texas
New Orleans
El Paso
35 °C
Phoenix
43 °C
Los Angeles
23 °C
24 °C
29 °C
10 °C
Moderna announces positive results for Omicron vaccine / Photo: © AFP
NYSE - LSE
| RBGPF | 5.47% | 76 | $ | |
| CMSD | -0.04% | 23.571 | $ | |
| SCU | 0% | 12.72 | $ | |
| JRI | -0.34% | 13.39 | $ | |
| BCC | -1.67% | 80.74 | $ | |
| CMSC | 0.04% | 23.06 | $ | |
| NGG | 0.31% | 71.23 | $ | |
| SCS | 0.5% | 15.96 | $ | |
| GSK | -0.24% | 37.71 | $ | |
| BCE | 0% | 24.35 | $ | |
| RELX | 0.08% | 48.04 | $ | |
| RIO | 0.45% | 62.14 | $ | |
| RYCEF | -0.07% | 14.34 | $ | |
| AZN | 0.72% | 74.07 | $ | |
| BTI | 1.87% | 58.33 | $ | |
| VOD | 1.3% | 11.51 | $ | |
| BP | -0.56% | 33.95 | $ |
Moderna announces positive results for Omicron vaccine
US biotech company Moderna on Wednesday announced positive results for a new vaccine that targets both the original Covid strain and Omicron.
This so-called "bivalent" vaccine was tested in a trial of more 850 adults, who had all received their first three doses of Moderna's original Spikevax vaccine.
Around half the group then received a fourth dose of Spikevax, while the rest received the bivalent vaccine.
Those who received the bivalent vaccine had significantly higher levels of neutralizing antibodies -- Y-shaped immune system proteins that block the virus -- against Omicron.
On average, these levels were around 75 percent higher in the group who got the bivalent vaccine as a fourth dose compared to those who got the original vaccine as a fourth dose. They also received slightly superior protection to the ancestral strain of Covid compared to Spikevax.
"We are thrilled," said Stephane Bancel, CEO of Moderna in a statement, adding he anticipated this vaccine would be the company's lead candidate for authorization as a booster this fall.
"We want to be as ready as early as August for shipping," he told investors in a call.
Stephen Hoge, the company's president, did concede that antibody levels would be lower against Omicron's sub variants that are now in circulation, but said he believed it was still a superior booster than repeating Spikevax.
The company doesn't yet have data on durability -- how the new vaccine booster will fare three months and six months out.
A panel of Food and Drug Administration experts will meet June 28 to discuss considerations and strategies for boosters in fall and winter.
R. Borges--JDB
